Exercise of Share Options and Total Voting Rights

RNS Number : 5733G
Aquis Exchange PLC
30 March 2022
 

30 March 2022

Aquis Exchange PLC

("Aquis" or the "Company")

  Exercise of Share Options

and

Total Voting Rights

 

Aquis Exchange PLC (AQX.L), the exchange services group, announces that it has received notification that an employee has exercised options under the Company's EMI Option Scheme over 2,666 ordinary shares of 10p each in the Company ("Ordinary Shares") at an exercise price of £3.47 per Ordinary Share.

Application has been made for 2,666 new Ordinary Shares to be admitted to trading on AQSE and AIM, which is expected to take place on 4 April 2022. The new Ordinary Shares will rank pari pasu with the existing Ordinary Shares in issue.

Total Voting Rights

In accordance with the provisions of the Disclosure Guidance and Transparency Rules of the FCA, the Company confirms that, following this issue, its issued share capital will comprise 27,508,115 Ordinary Shares. All Ordinary Shares shall have equal voting rights and none of the Ordinary Shares are held in treasury. Accordingly, the figure of 27,508,115 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

Aquis Exchange PLC

Tel: +44 (0)   7768 078 110

Belinda Keheyan, Head of Marketing

 

 

VSA Capital Limited (AQSE Corporate Adviser)

Tel: +44(0)20 3005 5000

Andrew Raca

 

Pascal Wiese

 

 

Liberum Capital Limited (Nominated Adviser and Joint Broker)

Tel: +44 (0) 20 3100 2000

Chris Clarke

 

Clayton Bush

 

Edward Thomas

 

Kane Collings

 

 

Canaccord Genuity Limited (Joint Broker)

Tel: +44 (0) 20 7523 8000

Bobbie Hilliam

 

Patrick Dolaghan

 

 

Alma PR (Financial PR Adviser)

Tel: +44 (0)20 3405 0209

Susie Hudson

aquis@almapr.co.uk

Kieran Breheny

 

Matthew Young

 

 

Notes to Editors

About Aquis Exchange

Aquis Exchange PLC is an exchange services group, which operates pan-European cash equities trading businesses (Aquis Exchange), growth and regulated primary markets (Aquis Stock Exchange/AQSE) and develops/licenses exchange software to third parties (Aquis Technologies).

Aquis Exchange is authorised and regulated by the UK Financial Conduct Authority and France's Autorité des Marchés Financiers to operate Multilateral Trading Facility businesses in the UK/Switzerland and in EU27 respectively. Aquis operates lit order books and does not allow aggressive non-client proprietary trading, which has resulted in lower market impact and signalling risk on Aquis than other trading venues in Europe. According to independent studies, trades on Aquis are less likely to lead to price movement than on other lit markets. Aquis uses a subscription pricing model which works by charging users according to the message traffic they generate, rather than a percentage of the value of each stock that they trade.

Aquis Stock Exchange (AQSE) is a stock market providing primary and secondary markets for equity and debt products. It is authorised as a Recognised Investment Exchange, which allows it to operate a regulated listings venue. The AQSE Growth Market is divided into two segments 'Access' and 'Apex', with different levels of admission criteria. The Access market focuses on earlier stage growth companies, while Apex is the intended market for larger, more established businesses.

Aquis Technologies is the software and technology division of Aquis Exchange PLC. It creates and licenses cutting-edge, cost-effective matching engine and trade surveillance technology for banks, brokers, investment firms and exchanges.

Aquis Exchange PLC (AQX.L) is listed on the Alternative Investment Market of the LSE (AIM) market. For more information, please go to www.aquis.eu  

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRFZGFFRGMGZZG
UK 100

Latest directors dealings